Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/54709
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12642]
Metadatos
Mostrar el registro completo del ítem
AN OVERVIEW OF MUCOSA- ASSOCIATED PROTOZOA: CHALLENGES IN CHEMOTHERAPY AND FUTURE PERSPECTIVES
Giardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
Reinfecção
Refratário ao tratamento
Droga reaproveitada
Giardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
Reinfection
Treatment-refractory
Repurposed drug
Afiliación
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Estudos Integrados em Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Estudos Integrados em Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Estudos Integrados em Protozoologia. Rio de Janeiro, RJ, Brasil.
Resumen en ingles
Parasitic infections caused by protozoans that infect the mucosal surfaces are widely
neglected worldwide. Collectively, Entamoeba histolytica, Giardia lamblia,
Cryptosporidium spp. and Trichomonas vaginalis infect more than a billion people in
the world, being a public health problem mainly in developing countries. However, the
exact incidence and prevalence data depend on the population examined. These
parasites ultimately cause pathologies that culminate in liver abscesses, malabsorption
syndrome, vaginitis, and urethritis, respectively. Despite this, the antimicrobial agents
currently used to treat these diseases are limited and often associated with adverse side
effects and refractory cases due to the development of resistant parasites. The paucity of
drug treatments, absence of vaccines and increasing problems of drug resistance are
major concerns for their control and eradication. Herein, potential candidates are reviewed
with the overall aim of determining the knowledge gaps and suggest future perspectives
for research. This review focuses on this public health problem and focuses on the
progress of drug repositioning as a potential strategy for the treatment of
mucosal parasites.
Palabras clave en portugues
Entamoeba histolyticaGiardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
Reinfecção
Refratário ao tratamento
Droga reaproveitada
Palabras clave en ingles
Entamoeba histolyticaGiardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
Reinfection
Treatment-refractory
Repurposed drug
Compartir